R Squared Ltd Invests $53,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

R Squared Ltd purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 960 shares of the company’s stock, valued at approximately $53,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TARS. FMR LLC raised its holdings in shares of Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after buying an additional 3,537 shares in the last quarter. SG Americas Securities LLC increased its position in Tarsus Pharmaceuticals by 87.5% in the 3rd quarter. SG Americas Securities LLC now owns 7,242 shares of the company’s stock valued at $238,000 after acquiring an additional 3,379 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Tarsus Pharmaceuticals by 64.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock worth $241,000 after purchasing an additional 2,879 shares during the last quarter. Hsbc Holdings PLC acquired a new position in shares of Tarsus Pharmaceuticals in the second quarter worth approximately $241,000. Finally, Intech Investment Management LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter worth approximately $282,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Up 3.9 %

TARS opened at $53.76 on Friday. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The business’s 50-day moving average price is $51.61 and its 200-day moving average price is $39.84. The company has a market cap of $2.06 billion, a P/E ratio of -14.11 and a beta of 1.02. Tarsus Pharmaceuticals, Inc. has a 12 month low of $20.08 and a 12 month high of $57.14.

Analyst Ratings Changes

A number of research analysts recently issued reports on TARS shares. The Goldman Sachs Group boosted their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. Barclays raised their price objective on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. Finally, Oppenheimer increased their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $56.00.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.